Pressure to contain opioid overuse in the United States is at a boiling point. The Centers for Disease Control and Prevention reports that overdose deaths linked to opioid prescriptions have increased fivefold over the last two decades. To reduce reliance on opioid prescriptions, the Centers for Medicare & Medicaid Services (CMS) and even some private payers have started offering some financial incentives for ambulatory surgery centers (ASCs) to use non-opioid alternatives.
Medicare typically packages drugs used in surgical procedures as a surgical supply under its Outpatient Prospective Payment System. This payment policy extends to Exparel, a bupivacaine liposome injectable suspension (Pacira Pharmaceuticals, Parsippany, New Jersey). The drug serves as a postsurgical anesthetic, issued as a single-dose infiltration or interscalene brachial plexus nerve block. Local and regional nerve blocks such as bupivacaine aren’t new, yet their popularity has grown in multimodal anesthesia/analgesia regimens to help patients move past postoperative surgical pain—a time when they usually need the most opioids.
In its 2019 final payment rule for outpatient facilities, CMS took steps to unbundle and pay ASCs separately for Exparel—thus offering a better rate to these facilities—and any other similar, evidence-based drugs that might be approved and covered for payment (sidebar at right). As of now, Exparel is the only drug that fits into this payment category.
Even before CMS’ measure took effect in January, Aetna last fall announced that it would start reimbursing a select group of ASCs in New Jersey and Florida for Exparel to encourage non-opioid postsurgical pain management regimens. Aetna currently has agreements with at least 80 facilities and is weighing its options to expand reimbursement to other ASCs.
Buoyed by opportunities to be reimbursed at a better rate for what is otherwise a costly drug, some ASC leaders are hopeful that Exparel will help them reduce opioid prescriptions and provide a convenient, effective onsite treatment for postoperative pain. “Anything we can do to reduce postop pain and subsequently reduce the use of opioids postop is a win,” says John Piccione, regional director of Surgery Partners in Palm Beach and Miami, Florida, which is taking part in Aetna’s pilot project and also expects to receive Medicare reimbursement for Exparel.
But he admits it’s not a fix-all. “What Exparel can’t do is take care of all pain at the site of the operation, specifically in the bone. You still need pain medications for that” (sidebar below).
In general, it has been cheaper and quicker for ASCs to prescribe pain medication and send patients home than to administer an expensive drug like Exparel, which costs about $170 for a 10-mL vial and $315 for a 20-mL vial.
That mindset may be changing, however. “I think times have changed, and opioid abuse is at the forefront in a lot of surgeons’ minds. Any attempt to curb opioid abuse should be well received,” says Gregory P. DeConciliis, PA-C, CASC, administrator of Boston Out-Patient Surgical Suites, LLC, Waltham, Massachusetts.
If there’s any resistance, it may come from surgeons who see Exparel as too expensive and have not been allowed to use it, even at the hospital. “Therefore, they have attempted to find their own ‘cocktail’ for pain control, or just have not adopted its use. This mindset will have to be broken,” DeConciliis says. As the indications for regional nerve blocks increase beyond interscalene, he adds: “I think you will find the use increasing for any potential patient with pain management issues, or a history of nausea/vomiting/or opioid abuse.”
Matt Pate, senior vice president for the service line strategy group at Texas-based United Surgical Partners International (USPI), doesn’t expect sweeping changes, but he anticipates that new reimbursement opportunities may spur ASCs to take on additional surgery cases that they wouldn’t have been able to do in the past. Several of USPI’s locations are participating in Aetna’s pilot project. “We’ve seen some physicians come to the ASCs after frustration with a hospital that would not add Exparel to their formulary,” says Pate.
Some ASC leaders are already rethinking their pain management regimens.
“We hadn’t been using Exparel, but we are adding it to our formulary,” says Tracy Hoeft-Hoffman, MSN, MBA, RN, CASC, administrator of Heartland Surgery Center, Kearney, Nebraska. Previously, the facility relied on opioids or sometimes nerve blocks such as Marcaine (bupivacaine hydrochloride) to decrease pain. Whereas Marcaine only lasts about 12 hours, Exparel is a special formulation of Marcaine that allows the nerve block to last up to 72 hours.
Adding Exparel to the pain management regimen should go a long way toward reducing opioid use, and will be a big assist in postoperative pain, especially for procedures such as total joints, Hoeft-Hoffman says. She adds that they may be able to use Exparel for other procedures such as anterior cruciate ligament reconstruction or general surgery.
Surgery Partners has already seen significant postoperative pain reduction with use of Exparel, along with reductions in opioid utilization and long-lasting reductions in surgical site pain.
Exparel is especially useful in reducing pain following joint replacements and lumbar fusion procedures that incise muscles in the patient’s back, says Piccione. “These patients are much more comfortable postop than in previous times, when Exparel wasn’t used,” he says. Reducing pain also translates into reduced recovery time in the postanesthesia care unit.
Although Exparel won’t eliminate the need for opioids, patients given Exparel will likely need a lower dose of opioids, Hoeft-Hoffman says. The adjustment for patients may come from the fact that Exparel is an injectable drug, not a prescription they take home with them. “With education related to Exparel and opioid use, I’d hope they’d be open to it,” Hoeft-Hoffman says.
Piccione says patients at his facilities have responded favorably to Exparel. “Fear of pain is one of the largest issues patients experience prior to having surgery, so patients are excited about anything that may reduce postoperative pain,” he says.
The injection takes place in a sterile environment at the conclusion of the procedure, while the patient is still under anesthesia. The patient awakens expecting to feel less pain.
The facility continues to use local anesthetics such as Marcaine. However, the advantage of Exparel is that its active ingredient bupivacaine is slowly released over time, providing several days of incisional and surrounding soft tissue numbness. And yes, it’s expensive, but because dilution rates are so favorable, usually one vial is adequate for any procedure, Piccione adds.
Exparel actually saves money for patients and facilities alike because it eliminates the need for pain pumps and additional postoperative medications, says Christina Rhodes, administrator of Cape Coral Surgery Center, Cape Coral, Florida, a subsidiary of Surgery Partners that started billing for the drug in January.
Piccione says he anticipates cost savings associated with reductions in patient length of stay, but currently doesn’t have enough comparative data to quantify that savings.
Some facilities that use Exparel are also taking steps to reexamine their opioid prescription regimens. “Internally, we are looking at opioid prescriptions along with our pharmacy consultant, and we are attempting to curb opioid overuse through appropriate prescription dosage and quantities,” DeConciliis says.
Looking beyond pain management regimens, it’s important to remember that opioid abuse solutions require a multifactorial approach, says Morteza Meftah, MD, attending surgeon at NYU Langone Orthopedic Hospital in New York City.
Dr Meftah has seen a dramatic decrease in opioid prescriptions in the past few years, mostly because of the national move to address the epidemic. “Even though there are some studies that show similar outcomes between Exparel and other pain medications, in our experience, it has made a difference for reducing pain, length of hospital stay, and ability to discharge to home.”
Patient education and expectations factor into this equation. “If patients are educated that the pain will be tolerable with a narcotic-sparing pathway, and they will have a better recovery with therapy and will avoid opioid side effects, they are open to it and willing to participate,” Dr Meftah says. ✥
Jennifer Lubell is a healthcare writer based in Rockville, Maryland.
https://www.govinfo.gov/content/pkg/FR-2018-11-21/pdf/2018-24243.pdf.